Gastrointestinal Microbiota and Mucosal Interface

The gastrointestinal microbiota and mucosal interface represent the interaction zone between the host’s intestinal epithelial barrier, overlying mucus layers, and the diverse microbial community that inhabits the gut. This interface is integral for nutrient absorption, maintenance of intestinal and systemic immune homeostasis, and protection against pathogens and toxins. The mucus layer provides habitat and separation, allowing commensal microbes to thrive while restricting direct access to the epithelium. Disruption in the structure or function of this interface (e.g., altered microbial composition, compromised mucus barrier) is associated with a range of diseases including inflammatory bowel disease, infection, metabolic disorders, and even central nervous system conditions via the gut-brain axis. Therapeutic strategies target the microbiota (via probiotics, prebiotics, antibiotics, FMT, and phages) and/or the barrier (promotion of mucus secretion, strengthening tight junctions) to restore homeostasis and manage disease.

Other names

Gut microbiota-mucosal interfaceMicrobiota-mucus layer interfaceIntestinal microbiota and mucosa

Drugs targeting this interface act by restoring or modulating microbial community composition (e.g., probiotics, FMT), selectively killing pathogenic bacteria (e.g., phage therapy, antibiotics), promoting beneficial metabolite production (e.g., prebiotics), or enhancing barrier function (e.g., certain probiotics/prebiotics that increase mucin secretion).